Aromyx

The core of Aromyx's business is a proprietary platform that uses biological receptors from the human nose and tongue to measure and analyze taste and scent. The technology places these cloned receptors onto a biosensor, the EssenceChip™, which generates a digital signal when exposed to flavor or fragrance molecules. This process creates a reproducible digital signature of a sensory experience, moving beyond subjective human panel testing. The collected data is then analyzed using AI and machine learning algorithms and stored in the Allegory™ database, creating a comprehensive library of sensory information. This allows for precise comparisons and predictions about consumer perception.

Aromyx followed a razor/razorblade business model, selling disposable EssenceChip™ biosensors and providing subscription-based access to its software suite and data analytics platform. The company served a broad client base, including Fortune 500 companies in the food and beverage, consumer packaged goods (CPG), chemical, and pharmaceutical sectors. For these clients, the technology offered a way to accelerate product development, improve quality control, refine flavors, and better understand consumer preferences across different demographics. For instance, it could help reformulate products with less sugar or predict how a new flavor would be received in a new market. In early 2023, the company announced a consumer-facing AI recommendation tool to suggest products based on an individual's unique taste and smell affinities.

Over its operational life, Aromyx secured approximately $20.9 million in funding across several rounds, including a $10 million Series A in July 2021, backed by investors such as Rabo Food&Ag Innovation Fund, SOZO Ventures, and Ulu Ventures. Despite its advancements and established client base, some data sources indicate the company ceased operations in early 2024.